Akebia Therapeutics, Inc. (AKBA) Stock Price & Analysis
Akebia Therapeutics, Inc. (AKBA) rose 0.00% to USD 1.22 as of July 25, 2026 at 04:58 UTC, according to Nexqual real-time market data.
AKBA last closed at USD 1.22; the session ranged USD 1.2–1.23 on volume of 1,459,815 shares. Market capitalization is $327.28M, with a 52-week range of USD 0.82–3.85 (NCM). Source: Nexqual, July 25, 2026 at 04:58 UTC.
Key Statistics (as of July 25, 2026 at 04:58 UTC)
| Price | USD 1.22 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.22 |
| Open | USD 1.23 |
| Day Range | USD 1.2 – 1.23 |
| 52-Week Range | USD 0.82 – 3.85 |
| Volume | 1,459,815 shares |
| Market Cap | $327.28M |
| Exchange | NCM |
Technical Analysis (AKBA)
Nexqual's technical model rates AKBA "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 04:58 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 50.11 (neutral) |
| vs SMA50 | Above (USD 1.12) |
| MACD | 0.04 (positive) |
Analyst Ratings (AKBA)
Wall Street analysts rate AKBA "None" based on 5 analysts, with a mean price target of USD 4.2 (range USD 3–6), per Nexqual as of July 25, 2026 at 04:58 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 4.2 |
| High Target | USD 6 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (AKBA)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.03 |
| Revenue Estimate | $48.86M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.03 vs est -0.02 ▼ miss |
| 2025-12-31 | USD -0.05 vs est -0.06 ▲ beat |
| 2025-09-30 | USD 0 vs est -0.01 ▲ beat |
| 2025-06-30 | USD 0.03 vs est -0.03 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:58 UTC.
Financials & Fundamentals (AKBA)
| Total Revenue | $232.40M |
|---|---|
| Revenue Growth (YoY) | -6.60% |
| Gross Margin | +81.94% |
| Operating Margin | -2.76% |
| Profit Margin | -8.83% |
| ROE | -78.95% |
| Debt / Equity | 721.55 |
| Current Ratio | 1.4 |
| Total Cash | $162.64M |
| Total Debt | $197.52M |
| Free Cash Flow | $65.81M |
Source: Nexqual, July 25, 2026 at 04:58 UTC.
Financial Health Score (AKBA)
Nexqual rates Akebia Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 04:58 UTC.
| Growth | Strong — Revenue +47% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 82%, operating -3% |
| Balance Sheet | Critical — $163M cash vs $198M debt |
| Cash Flow | Strong — FCF $66M, 28% margin |
| Efficiency | Critical — ROE -79%, ROA 2.0% |
Ownership (AKBA)
| Insider Ownership | +4.06% |
|---|---|
| Institutional Ownership | +42.15% |
| Shares Outstanding | 268.26M |
| Float | 262.01M |
| Short % of Float | +7.22% |
Source: Nexqual, July 25, 2026 at 04:58 UTC.
Leadership (AKBA)
Akebia Therapeutics, Inc. is led by John P. Butler (age 61), CEO, President & Director, per Nexqual as of July 25, 2026 at 04:58 UTC.
| CEO, President & Director | John P. Butler (age 61) |
|---|---|
| Chief Business Officer, Senior VP, CFO & Treasurer | Erik John Ostrowski (age 53) |
| Senior VP & Chief Technology Officer | Justin McCue |
| Senior Director of Investor & Corporate Communications | Mercedes Carrasco |
Major Backers & Investors (AKBA)
Notable institutional backers of Akebia Therapeutics, Inc. include Fidelity, Goldman Sachs, Citigroup Inc., according to Nexqual as of July 25, 2026 at 04:58 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 2.06% |
| Goldman Sachs | 1.34% |
| Citigroup Inc. | 1.06% |
| Bank of America Corporation | 1.03% |
| Qube Research & Technologies Ltd | 0.89% |
| Millennium Management | 0.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.97% |
| Vanguard Group | 9.8% |
| State Street | 4.33% |
| Geode Capital | 2.41% |
Source: Nexqual, July 25, 2026 at 04:58 UTC.
From Akebia Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
- Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
- The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.
- The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARDX | Ardelyx, Inc. | USD 5.03 | ▼ 0.98% |
| KYNB | Kyntra Bio, Inc. | USD 7.03 | ▼ 2.56% |
| KPTI | Karyopharm Therapeutics Inc. | USD 7.41 | ▲ 3.2% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.52 | ▼ 10.59% |
| ABEO | Abeona Therapeutics Inc. | USD 6.05 | ▼ 5.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:58 UTC. This page is informational and not investment advice.